Therefore, MBNL1, circNTRK2, and PAX5 might be effective targets in GBM treatment, possessing potential clinical value, but the survival analysis and targeted drugs of these marker in GBM remain to be elucidated. The gene discussed is PAX5; the disease is glioblastoma.